Browse Studies — Arctuva

Phase 1

A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or in Combination With Pomalidomide for Multiple Myeloma

The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses \[RP2Ds\]) and schedule for JN…

Multiple MyelomaSmoldering Multiple MyelomaImmunoglobulin Light-chain Amyloidosis

Estimated

~$150 – $4,200

Actual pay is set by the research site.